Delay for EU-US mutual recognition deal
This article was originally published in Clinica
The implementation date for the mutual recognition agreement on medical devices between the US and the European Union has been delayed until October 1 to give both sides more time to prepare for the accord.
You may also be interested in...
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.